These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2731776)

  • 1. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis.
    Francis RB
    Haemostasis; 1989; 19(2):105-11. PubMed ID: 2731776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease.
    Devine DV; Kinney TR; Thomas PF; Rosse WF; Greenberg CS
    Blood; 1986 Jul; 68(1):317-9. PubMed ID: 3719103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-dose warfarin on D-dimer levels during sickle cell vaso-occlusive crisis: a brief report.
    Ahmed S; Siddiqui AK; Iqbal U; Sison CP; Shahid RK; Sheth M; Patel DV; Russo LA
    Eur J Haematol; 2004 Mar; 72(3):213-6. PubMed ID: 14962240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease.
    Francis RB; Haywood LJ
    J Natl Med Assoc; 1992 Jul; 84(7):611-5. PubMed ID: 1629925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
    Kurantsin-Mills J; Ofosu FA; Safa TK; Siegel RS; Lessin LS
    Br J Haematol; 1992 Aug; 81(4):539-44. PubMed ID: 1390242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease.
    Qari MH; Dier U; Mousa SA
    Clin Appl Thromb Hemost; 2012; 18(2):195-200. PubMed ID: 21949038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of fibrinolytic protein (D-dimer) and fibrinopeptide A as markers of sickle cell anaemia vaso-occlusive crisis.
    Ekwere TA; Ebele U; Ekanem M; Ogunro PS
    Niger Postgrad Med J; 2014 Sep; 21(3):225-30. PubMed ID: 25331238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heamostatic and genetic predisposing factors for stroke in children with sickle cell anemia.
    Mourad H; Fadel W; El Batch M; Rowisha M
    Egypt J Immunol; 2008; 15(1):25-37. PubMed ID: 20306667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation changes during the steady state in homozygous sickle-cell disease in Jamaica.
    Leslie J; Langler D; Serjeant GR; Serjeant BE; Desai P; Gordon YB
    Br J Haematol; 1975 Jun; 30(2):159-66. PubMed ID: 1201207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
    Whelihan MF; Lim MY; Mooberry MJ; Piegore MG; Ilich A; Wogu A; Cai J; Monroe DM; Ataga KI; Mann KG; Key NS
    J Thromb Haemost; 2016 Oct; 14(10):1941-1952. PubMed ID: 27430959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raised D-dimer levels in acute sickle cell crisis and their correlation with chest X-ray abnormalities.
    Dar J; Mughal I; Hassan H; Al Mekki TE; Chapunduka Z; Hassan IS
    Ger Med Sci; 2010 Oct; 8():Doc25. PubMed ID: 21063468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor-positive monocytes expression in children with sickle cell disease: clinical implication and relation to inflammatory and coagulation markers.
    Ragab SM; Soliman MA
    Blood Coagul Fibrinolysis; 2016 Dec; 27(8):862-869. PubMed ID: 26761587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease.
    Nsiri B; Gritli N; Bayoudh F; Messaoud T; Fattoum S; Machghoul S
    Hematol Cell Ther; 1996 Jul; 38(3):279-84. PubMed ID: 8974793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of D dimer in patients with elevated fibrinogen degradation products in serum: further study in chronic myelogenous leukemia.
    Saito M; Asakura H; Jokaji H; Uotanzi C; Kumabashiri I; Yoshida T; Hashizume K; Matsuda T
    Acta Haematol; 1990; 84(3):149-55. PubMed ID: 2123066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the hypercoagulable state in patients with sickle cell disease.
    Shah N; Thornburg C; Telen MJ; Ortel TL
    Thromb Res; 2012 Nov; 130(5):e241-5. PubMed ID: 22959127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.
    Hyacinth HI; Adams RJ; Greenberg CS; Voeks JH; Hill A; Hibbert JM; Gee BE
    PLoS One; 2015; 10(8):e0134193. PubMed ID: 26305570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin D-dimer in thrombogenic disorders.
    Matsuo T; Kobayashi H; Kario K; Suzuki S
    Semin Thromb Hemost; 2000; 26(1):101-7. PubMed ID: 10805290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis.
    Nur E; van Beers EJ; Martina S; Cuccovillo I; Otten HM; Schnog JJ; Meijers JC; Mantovani A; Brandjes DP; Bottazzi B; Biemond BJ;
    Blood Cells Mol Dis; 2011 Mar; 46(3):189-94. PubMed ID: 21256776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
    Horan JT; Francis CW
    Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of hypercoagulability change in steady state and during vaso-occlusive crisis among Sudanese patients living with sickle cell disease.
    Mohamed EA; Elgari MM; Babker AM; Waggiallah HA
    Afr Health Sci; 2020 Mar; 20(1):392-396. PubMed ID: 33402927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.